Day: March 15, 2023

BriaCell to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual Meeting

Written by Customer Service on March 15, 2023. Posted in Public Companies.

PHILADELPHIA and VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, has been selected to present four posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting held from April 14 – 19, 2023 at Orange County Convention Center, Orlando, Florida. The available abstract titles and texts are based on previously-disclosed patient data. However, the posters presented at AACR will contain refreshed survival updates, new patient data, and potential late-breaking discoveries. Poster details include the following: Poster 1: Title: Whole cell antigen presenting immune stimulating cells (Bria-IMT) for the treatment of...

Olympian and Champion Surfer Carlos Muñoz Turns To SofPulse® For Accelerated Recovery After Invasive Shoulder Surgery

Written by Customer Service on March 15, 2023. Posted in Public Companies.

Los Angeles, CA, March 15, 2023 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced details today of the remarkable experience of one of its Scientific Advisory Board Members, Dr. Gary Berns, while overseeing the rehabilitation treatments of Olympian and Surfing Champion Carlos Muñoz, following a devastating shoulder injury and subsequent accelerated recovery from highly invasive shoulder surgery utilizing Endonovo’s SofPulse® medical device. SofPulse® treatments applied to Muñoz’s surgically repaired shoulder resulted in significantly reduced recovery time, allowing Muñoz to re-enter the World Surf League (WSL) rankings and Championship Tour surfing competitions, nearly a year earlier than expected. Muñoz Career Prior To His Severe Shoulder Injury Carlos Muñoz is a Costa Rican surfer who rose to fame in 2008...

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

Written by Customer Service on March 15, 2023. Posted in Public Companies.

CARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the Company will be presenting five posters at the American Association for Cancer Research (AACR) Annual Meeting 2023 to be held April 14-19 in Orlando, FL. The AACR Conference is a focal point of the cancer research community, where scientists, clinicians, other healthcare professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. The Company will be presenting four posters regarding its lead program, QN-302, and one poster regarding an in-vivo study...

Star Equity Holdings, Inc. Announces 2022 Fourth Quarter and Full Year Financial Results

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

Q4 2022 revenues and gross profit increased 8.8% and 34.8%, respectively, compared to Q4 2021 Q4 2022 net income increased to $1.9 million from $4.4 million loss in Q4 2021 Q4 2022 adjusted EBITDA increased to $3.1 million from $1.0 million in Q4 2021 OLD GREENWICH, Conn., March 15, 2023 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) (“Star Equity” or the “Company”), a diversified holding company, reported today its financial results for the fourth quarter (Q4) and year (FY) ended December 31, 2022. All 2022 and 2021 amounts in this release are unaudited. Following the sale of a portion of our Healthcare business in early 2021, all financial results for the 2022 and 2021 reporting periods, unless stated otherwise, relate to continuing operations, which include the Healthcare, Construction, and Investments...

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

Initiated U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC); initial results are expected in the first half of 2024Initiated U.S. Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC) and dosed the first patient; initial results expected in the third quarter of 2023 Presented results of the Phase 2 study of CTX-009 in combination with paclitaxel in patients with BTC at the 2023 ASCO GI Cancers Symposium Completed enrollment of the Phase 1 monotherapy arm of CTX-471 (CD137 agonistic antibody) and initiated enrollment in the combination arm of CTX-471 with KEYTRUDA® (pembrolizumab) in patients with select solid tumors; initial combination results are expected in the second half of 2023 Completed GMP manufacturing and toxicology studies of CTX-8371...

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting Cash balance of $201.7 million as of December 31, 2022; runway remains unchanged through Q4 2024 WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2022, and provided a corporate update. “We made considerable progress in 2022, including the filing and acceptance of two new INDs for our next generation CDK4/6 inhibitor and our first-in-class, highly selective SMARCA2 degrader. Our current clinical pipeline consists of four differentiated and internally...

Blink Charging Unveils Completely Redesigned Mobile EV Charger for Fleets and EV Driver Roadside Assistance

Written by Customer Service on March 15, 2023. Posted in Public Companies.

Faster, lighter, quieter, and more cost effective than before, Blink’s new portable EV charger provides EV fleets with range confidence and creates new service offering for roadside assistance providers Miami Beach, FL, March 15, 2023 (GLOBE NEWSWIRE) — Blink Charging Co. (Nasdaq: BLNK) (“Blink” or the “Company”), a leading owner and operator of electric vehicle (EV) charging equipment and services, today announced the immediate availability of its redesigned Blink mobile charger. The freestanding charger is built to provide emergency charging for stranded electric vehicles, directly addressing the needs of EV fleet operators, roadside assistance providers, insurance companies, auto manufacturers, and public roadway assistance programs. The Blink mobile charger is rated at 32 amps and charges an EV with up to 0.5 to 1 mile of range...

Progressive Reports February 2023 Results

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

MAYFIELD VILLAGE, OHIO, March 15, 2023 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for February 2023: February(millions, except per share amounts and ratios; unaudited) 2023 2022 ChangeNet premiums written $ 6,057.8 $ 4,625.7 31 %Net premiums earned $ 4,166.6 $ 3,626.1 15 %Net income $ 150.3 $ 61.6 144 %Per share available to common shareholders $ 0.25 $ 0.10 149 %Total pretax net realized gains (losses) on securities $ (117.1 ) $ (209.4 ) (44)%Combined ratio 95.1 93.7 1.4 pts.Average diluted equivalent common shares 587.0 586.3 0 % February(thousands; unaudited) 2023 2022 ChangePolicies in Force Personal Lines Agency – auto 8,039.7 7,805.6 3...

Form 8.3 – [EMIS GROUP PLC 14 03 2023] – (CGWL)

Written by Customer Service on March 15, 2023. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree EMIS GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Form 8.3 – [DEVRO PLC 14 03 2023] – (CGWL)

Written by Customer Service on March 15, 2023. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree DEVRO PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Day: March 15, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals